Venous Stasis Ulcers
1
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
RegeneRx BiopharmaceuticalsThymosin Beta 4
RevalesioRevera Wound Care
Regenesis BiomedicalProvant Device
Clinical Trials (3)
Total enrollment: 110 patients across 3 trials
Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
Start: Jul 2006Est. completion: Jan 200972 patients
Phase 2Completed
Feasibility Study to Evaluate the Safety of Topically Applied Revera in Subjects With Venous Leg Ulcers
Start: Mar 2008Est. completion: Oct 201013 patients
Phase 1Completed
Provant Therapy of Venous Stasis Ulcer Trial
Start: Nov 2009Est. completion: Nov 201125 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.